UA106131C2 - Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання - Google Patents

Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання

Info

Publication number
UA106131C2
UA106131C2 UAA201213609A UAA201213609A UA106131C2 UA 106131 C2 UA106131 C2 UA 106131C2 UA A201213609 A UAA201213609 A UA A201213609A UA A201213609 A UAA201213609 A UA A201213609A UA 106131 C2 UA106131 C2 UA 106131C2
Authority
UA
Ukraine
Prior art keywords
pains
prophylactic
therapeutic agent
diseases associated
urinary organs
Prior art date
Application number
UAA201213609A
Other languages
English (en)
Russian (ru)
Inventor
Акієсі Сомея
Хіроко Хаясіда
Май Кода
Масаюкі Танахасі
Кацуро Йосіока
Original Assignee
Астеллас Фарма Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Інк. filed Critical Астеллас Фарма Інк.
Publication of UA106131C2 publication Critical patent/UA106131C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Пропонується засіб для профілактики або лікування захворювань, які супроводжуються болем в органах сечовипускання, що містить піридильну неароматичну азотовмісну гетероцикло-1-карбоксилатну сполуку формули (І) EMBED MDLDrawOLE.MDLDrawObject.1 (І) або її сіль.
UAA201213609A 2010-04-28 2011-04-27 Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання UA106131C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010104262 2010-04-28
PCT/JP2011/060332 WO2011136308A1 (ja) 2010-04-28 2011-04-27 泌尿器疼痛を伴う疾患の予防又は治療剤

Publications (1)

Publication Number Publication Date
UA106131C2 true UA106131C2 (uk) 2014-07-25

Family

ID=44861604

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201213609A UA106131C2 (uk) 2010-04-28 2011-04-27 Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання

Country Status (13)

Country Link
US (1) US20130030006A1 (uk)
EP (1) EP2564849A4 (uk)
JP (1) JPWO2011136308A1 (uk)
KR (1) KR20130061684A (uk)
CN (1) CN102858340A (uk)
AU (1) AU2011246111B2 (uk)
BR (1) BR112012026876A2 (uk)
CA (1) CA2797420A1 (uk)
EA (1) EA201291122A1 (uk)
MX (1) MX2012012378A (uk)
TW (1) TW201206440A (uk)
UA (1) UA106131C2 (uk)
WO (1) WO2011136308A1 (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3264B1 (ar) * 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين
WO2016033776A1 (en) 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
TW201625591A (zh) 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
CN117510468A (zh) * 2017-03-13 2024-02-06 灵北拉荷亚研究中心公司 双重magl和faah抑制剂
MX2022007936A (es) * 2019-12-25 2022-10-27 Nippon Shinyaku Co Ltd Agente profilactico y/o terapeutico para la prostatitis cronica/sindrome de dolor pelvico cronico.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271015B1 (en) * 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
MX2007010076A (es) * 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
JP2006306746A (ja) * 2005-04-26 2006-11-09 Astellas Pharma Inc ピリジン−３−イルカルバメート誘導体
EP2610244A1 (en) * 2006-08-07 2013-07-03 Ironwood Pharmaceuticals, Inc. Indole compounds
US20090163508A1 (en) * 2007-10-10 2009-06-25 Takeda Pharmaceutical Company Limited Amide compound
TWI434842B (zh) * 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
BRPI0921692A2 (pt) * 2008-11-06 2018-06-26 Astellas Pharma Inc composto carbamato ou o sal do mesmo

Also Published As

Publication number Publication date
KR20130061684A (ko) 2013-06-11
WO2011136308A1 (ja) 2011-11-03
BR112012026876A2 (pt) 2016-07-19
JPWO2011136308A1 (ja) 2013-07-22
EP2564849A1 (en) 2013-03-06
EP2564849A4 (en) 2013-11-06
TW201206440A (en) 2012-02-16
US20130030006A1 (en) 2013-01-31
MX2012012378A (es) 2012-11-16
AU2011246111A1 (en) 2012-10-18
EA201291122A1 (ru) 2013-04-30
AU2011246111B2 (en) 2014-07-17
CA2797420A1 (en) 2011-11-03
CN102858340A (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
HK1140141A1 (en) Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
WO2012062925A3 (en) Compounds and methods for treating pain
NZ706836A (en) Methods of treating cancer
PH12014502029B1 (en) Treatment of cancer with tor kinase inhibitors
WO2012045090A3 (en) Therapeutic use of a tlr agonist and combination therapy
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2018102687A3 (en) Combination therapy for treating cancer
WO2013098416A3 (fr) Composes anti-douleur
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
UA106131C2 (uk) Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
NZ706740A (en) Use of vap-1 inhibitors for treating fibrotic conditions
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
WO2015061777A3 (en) Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
WO2010081662A3 (en) Methods for identifying patients who will respond well to cancer treatment
WO2016106357A8 (en) Combination of raf inhibitors and aurora kinase inhibitors